Acumen pharmaceuticals to present sabirnetug (acu193) fluid biomarker and target engagement analyses from phase 1 intercept-ad study in early alzheimer's at the ad/pd™ 2024 annual meeting

- oral presentation to explore drug effect of sabirnetug (acu193) on key cerebrospinal fluid biomarkers in early ad

ABOS Ratings Summary

ABOS Quant Ranking